Here, we investigated whether VPS4B expression is perturbed in cancer samples and whether VPS4A is a synthetic lethal partner for VPS4B. Our findings reveal a novel druggable target for further translational research toward personalized therapies for colorectal cancer (CRC) patients. Here, VPS4B is linked to cancer.